LakeShore Biopharma (NASDAQ:LSB), Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases and oncology indications. Headquartered in Pennsylvania, the company employs a strategy of identifying, in-licensing and acquiring assets that have demonstrated safety and preliminary efficacy, and advancing them through late-stage clinical trials. LakeShore’s pipeline includes small molecules and biologics targeting underserved patient populations with high unmet medical needs.
The company’s lead program, LBS-008 (celiprolol), is being evaluated for the treatment of vascular Ehlers–Danlos syndrome, a genetic connective tissue disorder associated with life-threatening arterial ruptures. In addition, LakeShore is developing LSB-126, an oral small molecule therapy for hereditary angioedema, and has an oncology portfolio that includes immuno-oncology candidates aimed at enhancing anti-tumor immune responses. By leveraging established safety profiles, LakeShore seeks to accelerate the path to regulatory approval and patient access.
Since its founding in 2006, LakeShore Biopharma has built a leadership team with deep experience in drug development, regulatory affairs and commercial strategy. Chief Executive Officer Scott Long brings more than two decades of biopharma leadership, while Chief Medical Officer Dr. Brian Schwartz leads clinical development efforts. The company’s board and executive management team have steered multiple late-stage programs to successful regulatory submissions and commercialization in rare disease markets.
LakeShore maintains its corporate headquarters in Philadelphia, with research operations and clinical trial management spread across North America and Europe. The company has established strategic partnerships with academic centers, patient advocacy groups and specialty pharmaceutical firms to support global clinical studies and prepare for potential market launch. Through these collaborations, LakeShore aims to deliver innovative therapies to patients with limited treatment options.
